Literature DB >> 30287988

Role of Plasma D-Dimer Levels in Breast Cancer Patients and Its Correlation with Clinical and Histopathological Stage.

Harish S1, Raxith Sringeri R1, Sarath Chandra P1.   

Abstract

Breast cancer, the most common female malignancy, represents a heterogeneous group of tumors, which presen both varied behaviors and response to therapy. This study was done with an attempt to evaluate the role of D-dimer in patients of carcinoma breast, in predicting lymph node metastasis in carcinoma patients and to look for relationship of these markers with histopathologic parameters. Clinical data was obtained from clinical examination of patients admitted in the Department of Surgery with history of breast lump and confirmed with fine needle aspiration cytology (FNAC). Clinical staging was done using TNM staging. D-dimer level was measured prior to commencement of treatment, i.e., modified radical mastectomy (MRM) or neoadjuvant chemotherapy and finally 6 months after surgery or completion of 6 cycles of chemotherapy. The characteristics of the study population Out of 60 study cases minimum age of the patient being 30 years and maximum being 74 years. Of all histopathologic variables examined, D-dimer levels directly correlated with extent of lymph node involvement and lymphovascular invasion, D-dimer levels correlated strongest with the number of positive lymph nodes, but not with tumor size, estrogen receptor status, and progesterone receptor status. This study clearly shows that plasma D-Dimer levels are elevated in carcinoma breast patients. Increased D-Dimer levels are an important marker of clinical stage, lymphovascular invasion, lymph node involvement, and tumor metastasis.

Entities:  

Keywords:  Bloom-Richardson grading; Breast cancer; D-Dimer; Early breast cancer; Metastasis

Year:  2017        PMID: 30287988      PMCID: PMC6154371          DOI: 10.1007/s13193-017-0682-x

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  11 in total

Review 1.  Bone marrow micrometastasis in breast cancer.

Authors:  S Ozbas; H Dafydd; A D Purushotham
Journal:  Br J Surg       Date:  2003-03       Impact factor: 6.939

2.  Triple-negative breast cancer: clinical features and patterns of recurrence.

Authors:  Rebecca Dent; Maureen Trudeau; Kathleen I Pritchard; Wedad M Hanna; Harriet K Kahn; Carol A Sawka; Lavina A Lickley; Ellen Rawlinson; Ping Sun; Steven A Narod
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

3.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases.

Authors:  C L Carter; C Allen; D E Henson
Journal:  Cancer       Date:  1989-01-01       Impact factor: 6.860

Review 4.  ERBB2 oncogene in human breast cancer and its clinical significance.

Authors:  F Révillion; J Bonneterre; J P Peyrat
Journal:  Eur J Cancer       Date:  1998-05       Impact factor: 9.162

5.  Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma.

Authors:  H Pereira; S E Pinder; D M Sibbering; M H Galea; C W Elston; R W Blamey; J F Robertson; I O Ellis
Journal:  Histopathology       Date:  1995-09       Impact factor: 5.087

6.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

7.  Inhibition of tissue factor signaling suppresses tumor growth.

Authors:  Henri H Versteeg; Florence Schaffner; Marjolein Kerver; Helle H Petersen; Jasimuddin Ahamed; Brunhilde Felding-Habermann; Yoshikazu Takada; Barbara M Mueller; Wolfram Ruf
Journal:  Blood       Date:  2007-09-27       Impact factor: 22.113

8.  Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer.

Authors:  Cheryl L Rock; Shirley W Flatt; Gail A Laughlin; Ellen B Gold; Cynthia A Thomson; Loki Natarajan; Lovell A Jones; Bette J Caan; Marcia L Stefanick; Richard A Hajek; Wael K Al-Delaimy; Frank Z Stanczyk; John P Pierce
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-03-06       Impact factor: 4.254

9.  HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer.

Authors:  Julie E Lang; Kailash Mosalpuria; Massimo Cristofanilli; Savitri Krishnamurthy; James Reuben; Balraj Singh; Isabelle Bedrosian; Funda Meric-Bernstam; Anthony Lucci
Journal:  Breast Cancer Res Treat       Date:  2008-03-09       Impact factor: 4.872

10.  Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.

Authors:  F Wärnberg; H Nordgren; L Bergkvist; L Holmberg
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

View more
  3 in total

1.  The association of D-dimer with clinicopathological features of breast cancer and its usefulness in differential diagnosis: A systematic review and meta-analysis.

Authors:  Yan Lu; LongYi Zhang; QiaoHong Zhang; YongJun Zhang; DeBao Chen; JianJie Lou; JinWen Jiang; ChaoXiang Ren
Journal:  PLoS One       Date:  2019-09-05       Impact factor: 3.240

Review 2.  The Research Progress on the Prognostic Value of the Common Hematological Parameters in Peripheral Venous Blood in Breast Cancer.

Authors:  Li Chen; Xiangyi Kong; Chengrui Yan; Yi Fang; Jing Wang
Journal:  Onco Targets Ther       Date:  2020-02-14       Impact factor: 4.147

3.  Diagnosis and Treatment of Male Accessory Breast Cancer: A Comprehensive Systematic Review.

Authors:  Liwei Pang; Meiying Cui; Wanlin Dai; Shuodong Wu; Jing Kong
Journal:  Front Oncol       Date:  2021-03-29       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.